4.6 Article

Rapid Polymerase Chain Reaction Assay to Detect Herpes Simplex Virus in the Genital Tract of Women in Labor

Journal

OBSTETRICS AND GYNECOLOGY
Volume 115, Issue 6, Pages 1209-1216

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/AOG.0b013e3181e01415

Keywords

-

Funding

  1. NIH [AI-30731]
  2. GlaxoSmithKline
  3. Abbott Laboratories
  4. Diasorin
  5. [K24 AI 071113]

Ask authors/readers for more resources

OBJECTIVE: To develop a rapid quantitative real-time polymerase chain reaction (PCR) to detect herpes simplex virus (HSV) in the genital secretions of women that may be used in labor. METHODS: Samples of genital secretions from women in labor, swabs of active genital lesions, and swabs of buffer solution were analyzed using a newly developed rapid HSV PCR assay to detect HSV glycoprotein B gene and quantitate virion copy number. A previously validated TaqMan PCR to detect HSV glycoprotein B gene was performed as the comparator gold standard. Positivity determination that optimized sensitivity and specificity was determined with receiver operating characteristic curves. RESULTS: The median time to result for rapid HSV PCR was 2 hours (range 1.5-3.5 hours). A positivity determination rule that required both wells of the rapid test to detect 150 copies or greater of HSV per milliliter maximized specificity (96.7%) without appreciable loss of sensitivity (99.6%). Among positive samples, the correlation between the rapid test and TaqMan for the quantity of HSV isolated was excellent (R = 0.96, P<.001). The rapid test had a positive predictive value of 96.7% and a negative predictive value of 99.6% in a population with HSV shedding prevalence of 10.8%, based on the prevalence of genital HSV previously found among HSV-2 seropositive women in labor. CONCLUSION: Rapid HSV PCR provides results with excellent sensitivity and specificity within a timeframe that could inform clinical decision making for identifying neonates at risk of neonatal HSV infection. (Obstet Gynecol 2010; 115: 1209-16)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Medicine, General & Internal

A Public Health COVID-19 Vaccination Strategy to Maximize the Health Gains for Every Single Vaccine Dose

Ruanne V. Barnabas, Anna Wald

ANNALS OF INTERNAL MEDICINE (2021)

Editorial Material Immunology

Behind the Scenes Heroes: The COVID-19 Vaccine Data and Safety Monitoring Board COMMENT

Lawrence Corey

JOURNAL OF INFECTIOUS DISEASES (2021)

Article Medicine, General & Internal

Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

L. Corey, P. B. Gilbert, M. Juraska, D. C. Montefiori, L. Morris, S. T. Karuna, S. Edupuganti, N. M. Mgodi, A. C. deCamp, E. Rudnicki, Y. Huang, P. Gonzales, R. Cabello, C. Orrell, J. R. Lama, F. Laher, E. M. Lazarus, J. Sanchez, I. Frank, J. Hinojosa, M. E. Sobieszczyk, K. E. Marshall, P. G. Mukwekwerere, J. Makhema, L. R. Baden, J. I. Mullins, C. Williamson, J. Hural, M. J. McElrath, C. Bentley, S. Takuva, M. M. Gomez Lorenzo, D. N. Burns, N. Espy, A. K. Randhawa, N. Kochar, E. Piwowar-Manning, D. J. Donnell, N. Sista, P. Andrew, J. G. Kublin, G. Gray, J. E. Ledgerwood, J. R. Mascola, M. S. Cohen

Summary: The study found that broadly neutralizing antibodies did not prevent HIV-1 acquisition more effectively than placebo, but analyses of VRC01-sensitive HIV-1 isolates indicated that prophylaxis with broadly neutralizing antibodies may be effective.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Editorial Material Immunology

The path to find an HIV vaccine

Glenda E. Gray, Lawrence Corey

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2021)

Editorial Material Medicine, General & Internal

SARS-CoV-2 Variants in Patients with Immunosuppression

Lawrence Corey, Chris Beyrer, Myron S. Cohen, Nelson L. Michael, Trevor Bedford, Morgane Rolland

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Medicine, Research & Experimental

T cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity

Rebecca Elyanow, Thomas M. Snyder, Sudeb C. Dalai, Rachel M. Gittelman, Jim Boonyaratanakornkit, Anna Wald, Stacy Selke, Mark H. Wener, Chihiro Morishima, Alexander L. Greninger, Michael Gale, Tien-Ying Hsiang, Lichen Jing, Michael R. Holbrook, Ian M. Kaplan, H. Jabran Zahid, Damon H. May, Jonathan M. Carlson, Lance Baldo, Thomas Manley, Harlan S. Robins, David M. Koelle

Summary: This study suggests that measuring T cell responses can provide reliable assessment of past SARS-CoV-2 infection and protective immunity. T cell responses showed significant correlations with neutralizing antibody titers and disease severity indicators. T cell testing demonstrated high sensitivity even after 6 months of infection, outperforming serology tests in identifying prior infection, especially in individuals with milder disease.

JCI INSIGHT (2022)

Article Medicine, General & Internal

Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial

Dean Follmann, Holly E. Janes, Olive D. Buhule, Honghong Zhou, Bethany Girard, Kristen Marks, Karen Kotloff, Michael Desjardins, Lawrence Corey, Kathleen M. Neuzil, Jacqueline M. Miller, Hana M. El Sahly, Lindsey R. Baden

Summary: This study evaluated the seropositivity of anti-nucleocapsid antibody (anti-N Ab) in mRNA-1273 vaccinees with breakthrough SARS-CoV-2 infection. The results showed a lower seroconversion rate in vaccinees, indicating the importance of considering vaccination status when interpreting seroprevalence and seropositivity data based solely on anti-N Ab testing.

ANNALS OF INTERNAL MEDICINE (2022)

Article Biology

Starting to have sexual intercourse is associated with increases in cervicovaginal immune mediators in young women: a prospective study and meta-analysis

Sean M. Hughes, Claire N. Levy, Fernanda L. Calienes, Katie A. Martinez, Stacy Selke, Kenneth Tapia, Bhavna H. Chohan, Lynda Oluoch, Catherine Kiptinness, Anna Wald, Mimi Ghosh, Liselotte Hardy, Kenneth Ngure, Nelly R. Mugo, Florian Hladik, Alison C. Roxby

Summary: This study investigated changes in immune mediators in the cervicovaginal tract of Kenyan AGYW before and after first sexual intercourse, and combined the results with two other studies through meta-analysis. The study found a significant increase in concentrations of immune mediators after first sex, with cumulative effects over time. These findings were consistent across three studies conducted on different continents.

ELIFE (2022)

Review Immunology

KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine

Corey Casper, Lawrence Corey, Jeffrey Cohen, Blossom Damania, Anne A. Gershon, David C. Kaslow, Laurie T. Krug, Jeffrey Martin, Sam M. Mbulaiteye, Edward S. Mocarski, Patrick S. Moore, Javier Gordon Ogembo, Warren Phipps, Denise Whitby, Charles Wood

Summary: This article summarizes the epidemiology and biology of Kaposi sarcoma herpesvirus (KSHV) as an overlooked but potentially vaccine-preventable infection. The unique epidemiology of this virus provides opportunities to prevent its cancers if an effective, inexpensive, and well-tolerated vaccine can be developed and delivered.

NPJ VACCINES (2022)

Article Virology

Dynamics of SARS-CoV-2 VOC Neutralization and Novel mAb Reveal Protection against Omicron

Linhui Hao, Tien-Ying Hsiang, Ronit R. Dalmat, Renee Ireton, Jennifer F. Morton, Caleb Stokes, Jason Netland, Malika Hale, Chris Thouvenel, Anna Wald, Nicholas M. Franko, Kristen Huden, Helen Y. Chu, Alex Sigal, Alex L. Greninger, Sasha Tilles, Lynn K. Barrett, Wesley C. Van Voorhis, Jennifer Munt, Trevor Scobey, Ralph S. Baric, David J. Rawlings, Marion Pepper, Paul K. Drain, Michael Gale

Summary: New variants of SARS-CoV-2 continue to emerge and evade immunity. Convalescence from the ancestral virus provides limited protection against variants. Vaccination enhances immunity against viral variants, but the protection is weaker against Omicron BA.1, and a three-dose vaccine regimen provides significantly better protection against it compared to a two-dose.

VIRUSES-BASEL (2023)

Article Medicine, Research & Experimental

Novel engineered chimeric engulfment receptors trigger T cell effector functions against SIV-infected CD4+T cells

Daniel Corey, Francoise Haeseleer, Joe Hou, Lawrence Corey

Summary: Adoptive therapy using genetically engineered T cells shows promise in treating infectious diseases in immunocompromised individuals. In this study, chimeric engulfment receptor (CER) T cells designed to recognize phosphatidylserine (PS)-expressing cells successfully eliminated SIV-infected cells. The introduction of innate immune functions into T cells enhances the elimination of SIV-infected cells, and further in vivo studies are needed to evaluate their effectiveness.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2023)

Editorial Material Ethics

Ancillary Care Obligations of Clinical Trial Investigators in the COVID-19 Pandemic

Tara M. Babu, Anna Wald

AMERICAN JOURNAL OF BIOETHICS (2023)

Article Immunology

Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women

Deborah Donnell, Fei Gao, James P. Hughes, Brett Hanscom, Lawrence Corey, Myron S. Cohen, Srilatha Edupuganti, Nyaradzo Mgodi, Helen Rees, Jared M. Baeten, Glenda Gray, Linda-Gail Bekker, Mina Hosseinipour, Sinead Delany-Moretlwe

Summary: This study used counterfactual placebo comparisons using other data sources to evaluate the efficacy of antiretroviral agents for HIV pre-exposure prophylaxis. The findings showed that injectable cabotegravir (CAB-LA) and daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) can significantly reduce the risk of HIV infection compared to no intervention, and the efficacy of FTC/TDF against counterfactual placebo was consistent with previous placebo-controlled trials.

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2023)

Article Medicine, Research & Experimental

Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months

Magdalena E. Sobieszczyk, Jill Maaske, Ann R. Falsey, Stephanie Sproule, Merlin L. Robb, Robert W. Frenck, Hong-Van Tieu, Kenneth H. Mayer, Lawrence Corey, Kathleen M. Neuzil, Tina Tong, Margaret Brewinski Isaacs, Holly Janes, Himanshu Bansal, Lindsay M. Edwards, Justin A. Green, Elizabeth J. Kelly, Kathryn Shoemaker, Therese Takas, Tom White, Prakash Bhuyan, Tonya Villafana, Ian Hirsch

Summary: AZD1222 vaccine demonstrated safety, efficacy, and immunogenicity in the ongoing phase 3 trial. The vaccine provided durable protection with a significant reduction in the incidence of symptomatic COVID-19 and showed high efficacy against severe/critical disease. Humoral immune responses induced by AZD1222 waned over time.

JOURNAL OF CLINICAL INVESTIGATION (2022)

Article Multidisciplinary Sciences

After the pandemic: perspectives on the future trajectory of COVID-19

Amalio Telenti, Ann Arvin, Lawrence Corey, Davide Corti, Michael S. Diamond, Adolfo Garcia-Sastre, Robert F. Garry, Edward C. Holmes, Phillip S. Pang, Herbert W. Virgin

Summary: This article discusses the future patterns of SARS-CoV-2 infection, the development of variants, and the implications for vaccine deployment. It suggests that the virus may become endemic fueled by pockets of susceptible individuals and waning immunity. Effective surveillance and response are crucial to prevent new epidemic or pandemic patterns.

NATURE (2021)

No Data Available